Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

Trial Details

NCT ID
NCT06209606
Phase
EARLY_PHASE1
Sponsor
Oncotherapeutics
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Ruxolitinib Oral Tablet [Jakafi]
  • Lenalidomide
  • Methylprednisolone
Locations (sample)
  • West Hollywood, California, United States|34.09001,-118.36174

Key Eligibility Criteria

  • Subjects must meet all the following inclusion criteria to be eligible to enroll in this study.
  • Has a diagnosis of MM based on standard criteria as follows:
  • Major criteria:
  • Plasmacytomas on tissue biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →